{
  "source": "PA-Notification-Dry-Eye-Disease.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 1088-16\nProgram Prior Authorization-Notification\nMedication Cequa™ (cyclosporine 0.09% ophthalmic solution)*, Miebo™\n(perfluorohexyloctane), Restasis® (cyclosporine 0.05% ophthalmic\nemulsion), Restasis MultiDose™ (cyclosporine 0.05% ophthalmic\nemulsion)*, Tyrvaya™ (varenicline nasal spray), Vevye™\n(cyclosporine 0.1%)*, Xiidra® (lifitegrast 5% ophthalmic solution)\nP&T Approval Date 3/2006, 3/2007, 8/2008, 8/2009, 9/2010, 3/2011, 2/2012, 2/2013,\n4/2014, 4/2015, 3/2016, 12/2016, 9/2017, 9/2018, 3/2019, 4/2020,\n4/2021, 12/2021, 12/2022, 9/2023, 3/2024, 7/2024\nEffective Date 8/18/2024\n1. Background:\nCequa (cyclosporine 0.09% ophthalmic solution)*, Restasis (cyclosporine 0.05% ophthalmic\nemulsion) and Restasis MultiDose (cyclosporine 0.05% ophthalmic emulsion)*, are indicated to\nincrease tear production in patients whose tear production is presumed to be suppressed due to\nocular inflammation associated with keratoconjunctivitis sicca.\nMiebo (perfluorohexyloctane), Tyrvaya (varenicline nasal spray), Vevye (cyclosporine 0.1%)*\nand Xiidra (lifitegrast 5% ophthalmic solution) are indicated for the treatment of the signs and\nsymptoms of dry eye disease.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Cequa*, Miebo, Restasis, Restasis MultiDose*, Tyrvaya, Vevye* or Xiidra will be\napproved based on the following criterion:\na. Diagnosis of one of the following:\n1) Moderate to severe keratoconjunctivitis sicca\n2) Dry Eye Disease\n-AND-\nb. Medication will not be used in combination with another prescription product\nfor dry eye disease or keratoconjunctivitis sicca\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Cequa*, Miebo, Restasis, Restasis MultiDose*, Tyrvaya, Vevye* or Xiidra will be\napproved based on the following criterion:\na. Patient has demonstrated clinically significant improvement with therapy\n© 2024 UnitedHealthcare Services, Inc.\n-AND-\nb. Medication will not be used in combin",
    "oved based on the following criterion:\na. Patient has demonstrated clinically significant improvement with therapy\n© 2024 UnitedHealthcare Services, Inc.\n-AND-\nb. Medication will not be used in combination with another prescription product for\ndry eye disease or keratoconjuctivitis sicca\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n*Cequa, Restasis MultiDose and Vevyeare typically excluded from coverage.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n• Prior Authorization – Medical Necessity may be in place.\n4. References:\n1. Cequa [package insert]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc; December 2022\n2. Miebo [package insert]. Bridgewater, NJ: Bausch & Lomb Americas Inc; May 2023.\n3. Restasis [package insert]. Irvine CA: Allergan, Inc.: July 2017.\n4. Restasis MultiDose [package insert]. Irvine, CA: Allergan, Inc.; October 2016.\n5. Tyrvaya [package insert]. Princeton NJ: Oyster Point Pharma, Inc; February 2024.\n6. Vevye [package insert]. Nashville, TN: Harrow Eye, LLC; November 2023.\n7. Xiidra [package insert]. Bridgewater, NJ: Bausch & Lomb Americas Inc; December 2023.\n6. American Academy of Ophthalmology. Dry Eye Syndrome Preferred Practice Pattern 2023.\nProgram Notification – Dry Eye Disease\nChange Control\n4/2014 No changes to criteria. Updated references.\n4/2015 Updating authorization criteria to 6 months and reauthorization criteria\nto 12 months to align with prior authorization-medical necessity criteria\n3/2016 Removed the Prior Authorization-Medical",
    "4/2015 Updating authorization criteria to 6 months and reauthorization criteria\nto 12 months to align with prior authorization-medical necessity criteria\n3/2016 Removed the Prior Authorization-Medical Necessity program language.\n12/2016 Updated criteria to allow for Dry Eye Disease. Added Xiidra to criteria.\nChanged name of criteria to Dry Eye Disease.\n9/2017 Annual review. Administrative updates. Added Restasis MultiDose.\nUpdated references.\n9/2018 Annual review. Administrative updates and updated references.\n12/2018 Administrative change to add statement regarding use of automated\nprocesses.\n3/2019 Added Cequa and updated references.\n4/2020 Annual review. Removed extemporaneously compounded cyclosporine\ncriteria. Updated references.\n4/2021 Annual review. Updated references.\n12/2021 Added Tyrvaya.\n© 2024 UnitedHealthcare Services, Inc.\n12/2022 Annual review. Added state mandate language. Updated references.\n9/2023 Added Miebo and Vevye. Updated references.\n3/2024 Updated initial authorization to 12 months. Updated references.\n7/2024 Added concomitant therapy language. Updated references.\n© 2024 UnitedHealthcare Services, Inc."
  ]
}